Furthermore, studies suggest that NSCLC patients with concurrent EGFR and PIK3CA mutations experience significantly shorter progression times and reduced overall survival when treated with EGFR-TKI therapy, compared to those with only EGFR mutations (17, 38). The gene discussed is PIK3CA; the disease is non-small cell lung carcinoma.